Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage
biopharmaceutical company developing nucleic acid therapeutics for
patients with cancer and rare diseases, and The Myositis Association
(TMA), the only nonprofit organization dedicated to solely serving all
patients with inflammatory myopathies, today announced a collaboration
to advance a new potential treatment approach for polymyositis and
dermatomyositis known as Toll-like receptor (TLR) antagonism.
for Idera Pharmaceuticals and The Myositis Association Join Forces to Advance the Clinical Development of a Novel TLR Antagonist, IMO-8400, for the Treatment of Myositis investment picks